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RESEARCH ARTICLE STEM CELLS AND REGENERATION
LIF supports primitive endoderm expansion during
pre-implantation development
Sophie M. Morgani and Joshua M. Brickman*
ABSTRACT
Embryonic stem cells (ESCs) are pluripotent cell lines that can be
maintained indefinitely in an early developmental state. ESC culture
conditions almost always require the cytokine LIF to maintain self-
renewal. As ESCs are not homogeneous but contain multiple
populations reminiscent of the blastocyst, identifying the target cells
of LIF is necessary to understand the propagation of pluripotency.
We recently found that LIF acts under self-renewing conditions to
stimulate the fraction of ESCs that express extraembryonic markers,
but has little impact on pluripotent gene expression. Here, we report
that LIF has two distinct roles: it blocks early epiblast (Epi)
differentiation, and it supports the expansion of primitive endoderm
(PrE)-primed ESCs and PrE in vivo. We find that activation of JAK/
STAT signalling downstream of LIF occurs initially throughout the pre-
implantation embryo, but later marks the PrE. Moreover, the addition
of LIF to cultured embryos increases the GATA6+ PrE population,
whereas inhibition of JAK/STAT signalling reduces both NANOG+
epiblast andGATA6+ PrE. The reduction of the NANOG+ Epi might be
explained by its precocious differentiation to later Epi derivatives,
whereas the increase in PrE is mediated both by an increase in
proliferation and inhibition of PrE apoptosis that is normally triggered
in embryos with an excess of GATA6+ cells. Thus, it appears that the
relative size of the PrE is determined by the number of LIF-producing
cells in the embryo. This suggests a mechanism by which the embryo
adjusts the relative ratio of the primary lineages in response to
experimental manipulation.
KEY WORDS: Apoptosis, Blastocyst, Embryonic stem cell, GATA6,
LIF, Primitive endoderm
INTRODUCTION
Embryonic stem cells (ESCs) are karyotypically normal self-
renewing cell lines derived from the mammalian embryo during pre-
implantation development. They are typically considered to be
pluripotent, able to give rise to all lineages of the future embryo
when reintroduced into an embryo or differentiated in vitro (Evans
and Kaufman, 1981; Martin, 1981; Smith et al., 1988; Williams
et al., 1988; Beddington and Robertson, 1989). ESCs are derived
from the mammalian blastocyst at the stage when the inner cell mass
(ICM) contains a heterogeneous mix of progenitors of two lineages,
the epiblast (Epi) that will give rise to the embryo proper, and the
primitive endoderm (PrE) that will give rise to the extraembryonic
visceral and parietal endoderm (Chazaud et al., 2006). Like the
ICM, ESC cultures are heterogeneous and contain populations
primed towards both Epi and PrE (Chambers et al., 2007; Singh
et al., 2007; Hayashi et al., 2008; Toyooka et al., 2008; Kobayashi
et al., 2009; Canham et al., 2010). However, in ESC cultures these
progenitors are in a dynamic equilibrium (Canham et al., 2010;
Morgani et al., 2013; Morgani and Brickman, 2014; Posfai et al.,
2014).
The in vitro culture of ESCs can be supported by a number of
factors, but typically require Leukaemia inhibitory factor (LIF)
(Smith et al., 1988; Williams et al., 1988; Ying et al., 2003,
2008). In defined culture conditions, containing small molecule
inhibitors of GSK3 and MAPK (2i) (Ying et al., 2008), LIF is
required for efficient clonal expansion. However, when LIF is
removed from 2i, ESCs do not differentiate. Hence, it is a suitable
cell culture system to study the immediate early effects of LIF in
the absence of differentiation-related gene expression changes. In
ESCs, LIF binds to a heterodimeric receptor complex composed
of the LIF receptor (LIFR) and Glycoprotein 130 (GP130).
Binding to the receptor complex results in activation of JAK
tyrosine kinases that, in turn, phosphorylate the transcription
factor STAT3. This results in STAT3 dimerization and
translocation to the nucleus where it can activate target genes
(Hirai et al., 2011). Whereas there are other signalling pathways
downstream of LIF (Burdon et al., 2002; Liu et al., 2007;
Annerén, 2008), activation of STAT3 is necessary and sufficient
to support ESC self-renewal (Niwa et al., 1998; Matsuda et al.,
1999). A second cytokine that acts through GP130 to activate
JAK/STAT, IL-6, has also been implicated in pre-implantation
development (Do et al., 2013) and can replace LIF as a means to
sustain ESC self-renewal (Yoshida et al., 1994).
Although LIF supports ESC self-renewal, under standard
conditions embryonic mutations of LIF pathway components do
not show pre-implantation phenotypes (Li et al., 1995; Ware et al.,
1995; Takeda et al., 1997; Nichols et al., 2001; Do et al., 2013).
However, certain mammals have the ability to arrest development
reversibly at the blastocyst stage as a result of suboptimal
conditions, such as nutrient scarcity, a phenomena known as
diapause. Development can subsequently resume under more
favourable conditions. Diapause can therefore be seen as a
developmental mechanism to support sustained pluripotency, and
the induction of diapause can be used to improve ESC derivation
(Nichols et al., 2001). When diapause is induced, gp130−/−
embryos exhibit a complete loss of the pluripotent Epi population
(Nichols et al., 2001), indicating that LIF might play a role in vivo in
maintaining pluripotency, but that it is not required during normal
embryonic development. However, it is also possible that JAK/
STAT signalling is activated via a GP130-independent maternal
mechanism during early development that masks a pre-implantation
phenotype. Consistent with this, inhibiting downstream signalling,
either through pharmacological inhibition of JAK or in embryos in
which both maternal and zygotic Stat3 have been removed,
suggested that ICM maintenance requires active JAK/STAT
signalling (Do et al., 2013).Received 2 April 2015; Accepted 19 August 2015
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Here, we show that LIF acts through a two-pronged mechanism to
support ICM expansion, both in vivo and in vitro, in ESCs. LIF acts
to suppress Epi differentiation and also to support PrE expansion.
We had previously demonstrated that LIF promotes the expansion of
an extraembryonic-primed population of cells within ESC cultures
(Morgani et al., 2013), consistent with its well-characterised role in
extraembryonic development and implantation (Stewart et al., 1992;
Takahashi et al., 2003; Poehlmann et al., 2005; Prakash et al., 2011).
We show that LIF supports this population via JAK/STAT
signalling, the same pathway that promotes ESC self-renewal
(Niwa et al., 1998; Matsuda et al., 1999). We find that STAT3
phosphorylation correlates with a PrE rather than Epi identity
in vivo, and that LIF stimulates PrE survival and proliferation,
whereas inhibition of JAK activity leads to enhanced apoptosis in
the PrE. We hypothesise that LIF maintains ESC self-renewal and
ICM expansion by enhancing the survival of an extraembryonic-
primed population that provides paracrine factors for Epi expansion.
RESULTS
LIF promotes an extraembryonic ESC population through the
JAK/STAT pathway
We have previously shown that LIF promotes a population of ESCs
primed towards an extraembryonic fate (Morgani et al., 2013),
marked by the expression of a highly sensitive fluorescent reporter
for the endoderm marker Hhex [Hhex-Venus (HV)] (Canham et al.,
2010). We tested whether this was a general property of signalling
through GP130, as other members of the same cytokine family, such
as IL-6, have also been associated with self-renewal (Conover et al.,
1993; Rose et al., 1994; Wolf et al., 1994; Yoshida et al., 1994;
Pennica et al., 1995). Fig. 1A shows that not only can IL-6 induce
HV expression but also, at a high dose, it induces elevated levels of
this transgene compared with LIF treatment. HV ESCs were
cultured in 2i, to prevent differentiation in the absence of LIF, with
increasing doses of IL-6. Expression of the HV reporter was
assessed by flow cytometry (Fig. 1A). As previously reported
(Morgani et al., 2013), we observed HV induction in 2i/LIF and
obtained similar levels of HV expression with a low dose of IL-6
(500 ng/ml, Fig. 1A). At 1000 units, the effect of LIF on the HV
population becomes saturated (Morgani et al., 2013), but HV
expression can be further increased with high doses of IL-6
(1000 ng/ml, Fig. 1A).
LIF was previously shown to alter the relative number of
actively proliferating cells within the embryonic and
extraembryonic-primed ESC populations (Morgani et al., 2013).
Consistent with this, when LIF was added to ESCs cultured in 2i,
HV expression gradually increased over several days (Fig. S1A).
This observation was confirmed by qRT-PCR, with PrE genes
exhibiting a delayed response to LIF, including HHex, Hnf4a,
Dab2 and Sox17, contrasting with the rapid response (within 1 h)
of the immediate early target of LIF signalling, Socs3, or the
sharp threshold responses of LIF transcriptional components,
Stat3 and Klf4, at 8-24 h (Fig. 1B). Although Gata4 demonstrated
an early response to LIF, as with other PrE markers, the
expression change was gradual (Fig. 1B). Previous microarray
data showed that LIF also increased the expression of extracellular
matrix (ECM) genes associated with PrE development (Morgani
et al., 2013). Here, we observed that these genes also increased in
expression at 8-24 h (Fig. 1B; Fig. S1B). Interestingly, we
observed that mesoderm and ectoderm markers, including Lhx1,
Cdx2, Wnt3, Otx2 and Fgf5, were rapidly downregulated between
1 and 8 h following LIF addition, prior to changes in PrE gene
expression (Fig. 1B; Fig. S1B).
As LIF acts on multiple downstream pathways (Burdon et al.,
2002; Liu et al., 2007; Annerén, 2008), we tested which pathway
was required for HV induction. We found that JAK/STAT
signalling, also crucial for ESC self-renewal, supported the
expansion of the HV PrE-primed population. HV ESCs were
cultured in 2i or 2i/LIF medium in the presence of small molecule
inhibitors of the PI3K (LY) and JAK/STAT (JAKi) pathways. After
3 days of culture in these conditions, HV ESCs were analysed by
flow cytometry. Induction of HV was blocked by inhibition of JAK/
STAT, but not PI3K (Fig. 1C). Although GP130 can also signal
through activation of MAPK, all cells were cultured in 2i,
containing a block to MEK, and hence MAPK signalling was not
required for the induction of HV expression in response to LIF.
We found that LIFR was expressed heterogeneously within ESC
cultures (Fig. 1D) and at higher levels in the HV-positive (HV+)
compared with the HV-negative (HV−) population (Fig. 1E). This
suggests that the pathway is differentially activated in PrE and Epi
progenitors. Antibody staining of ESCs for the LIF targets
(Bourillot et al., 2009; Niwa et al., 2009; van Oosten et al., 2012)
phosphorylated STAT3 (pSTAT3) and KLF4 suggested that,
although there is some overlap with expression of the Epi marker
NANOG, this could not account for the all of the KLF4+ or
pSTAT3+ cells. KLF4 expression was heterogeneous and showed
some degree of co-expression with both NANOG and HV (Fig. 1F).
Owing to a lack of appropriate antibody combinations, we could not
co-stain for pSTAT3 and HV. However, although there was some
co-expression of pSTAT3 and NANOG, there were also cells that
expressed high levels of NANOG but low levels of pSTAT3 and,
vice versa, a fraction of cells that only expressed pSTAT3 (Fig. 1G),
probably corresponding to the HV population.
pSTAT3 is associated with extraembryonic lineages in the
pre-implantation embryo
We assessed the localisation of pSTAT3 and its target KLF4,
throughout pre-implantation development and also quantified their
expression within individual cells using CellProfiler (Carpenter
et al., 2006; Kamentsky et al., 2011) (Figs 2 and 3). We validated
this method by quantifying immunostaining of the three well-
characterised lineage markers NANOG (Epi), GATA6 (PrE) and
CDX2 (trophoblast) (Fig. S2). Although there are low levels of
NANOG expression at the 2-cell stage (Figs 2 and 3; Fig. S2),
approximately tenfold lower than in the late blastocyst, no obvious
nuclear staining was observed, suggesting that this is likely to be a
non-specific signal. Both inbred C57BL/6 and outbred CD1 mouse
lines were analysed but, as results were comparable between
different genetic backgrounds, data were combined (see Materials
and Methods). The analysis in Fig. S2B shows the progressive
segregation of these three lineages and suggests some new
correlations; for example, at the 8-cell stage all NANOG+ cells
are expressing CDX2, but not the reverse.
Strikingly, although there was an early correlation between
NANOG and pSTAT3, this was lost by the late-blastocyst stage
(Fig. 2) after the PrE and Epi had segregated, prior to Epi
differentiation. This contrasts with the overlap of NANOG with
pSTAT3 that we observed in ESCs (Fig. 1G). As in ESCs, there was
a correlation between KLF4 and NANOG, although KLF4 was also
expressed at low levels within the PrE (Fig. 3).
pSTAT3 is first observed in some, but not all, 2-cell embryos, but
was present in all cells of the 8-cell morula (Fig. 2A,B). pSTAT3was
also observed in all cells until the early blastocyst stage [embryonic
day (E) 3.5], when it became heterogeneous within the ICM and in
some trophoblast cells (Fig. 2A). At this stage, pSTAT3 showed a
3489











Fig. 1. See next page for legend.
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strong correlation with both GATA6 and NANOG expression
(Fig. 2A,B). By the late blastocyst stage (E4.5), pSTAT3 and
GATA6 remained correlated, and therewas nowa significant negative
correlation between NANOG and pSTAT3 (Fig. 2B; *P=0.04).
pSTAT3was expressed almost exclusively in the extraembryonic PrE
and trophoblast, and only at low levels within the Epi (Fig. 2A,B).
KLF4 was also expressed from the 2-cell stage and continued to
be expressed in all cells until the early blastocyst stage (E3.5)
(Fig. 3A,B). KLF4, as in ESCs, was then heterogeneously
expressed, overlapping with both the NANOG+ and GATA6+
populations (Fig. 3A,B). In the late blastocyst (E4.5), KLF4 was
expressed both in the Epi and PrE, although at a lower level in the
PrE (Fig. 3A,B). As it is highly expressed in the Epi, KLF4 appeared
correlated with NANOG expression at this late blastocyst stage.
We also quantified the correlation between pSTAT3 and KLF4
expression and observed that, although at the early blastocyst stage
there is a correlation between these markers, this decreases by the
late blastocyst (Fig. S3A,B).
Embryo culture in the presence of LIF promotes PrE cell
expansion
As we observed that the JAK/STAT pathway promoted an
extraembryonic fate in ESCs, and that pSTAT3 was associated
with the extraembryonic lineages in vivo, we tested whether LIF
could regulate lineage choice in vivo. Embryos were cultured from
E2.5 for 3 days, until the late blastocyst (equivalent of E4.5 in vivo),
the time period that the decision between Epi and PrE fates is being
made, in the presence or absence of LIF. As shown in Fig. 4, LIF
produces an apparent increase in the fraction of GATA6+ PrE, but
has little effect on NANOG.
Although the observation shown in Fig. 4 is robust, there is a
range of phenotypes, and we aimed to quantify the impact of LIF on
PrE versus Epi specification. Based on counting cells in control
ICMs, i.e. those cultured in only KSOM, we observed a fraction of
embryos that had a significantly higher than average proportion of
either GATA6+ or NANOG+ cells within the ICM (Fig. S4A,B;
P=0.0025 and 0.0003, respectively). As we observed a variation in
the number of GATA6+ and NANOG+ cells within ICMs, we
assigned embryos as ‘GATA6Hi’ and ‘NANOGHi’ if the average
proportion of GATA6+ or NANOG+ ICM cells was outside of
one standard deviation (s.d.) of control embryos (Fig. S4A,B and
Fig. S5A). Conversely, ‘normal’ embryos were within 1 s.d. of the
proportion of GATA6+ or NANOG+ ICM cells in controls
(Fig. S4A,B and Fig. S5A). There was no significant difference in
the total number of cells in embryos from each of these
categories, indicating that this variation was not due to disparity
of developmental stage (Fig. S4C). When embryos were cultured in
the presence of LIF from E2.5 until the late blastocyst, we observed
a corresponding increase in the level of pSTAT3 and in both the PrE
and Epi (Fig. S5B). However, pSTAT3 continued to be present at
levels approximately threefold higher in the PrE than in the Epi
(Fig. S5B). KLF4 also showed an increase in expression in both Epi
and PrE, and was now expressed at similar levels in both cell types
(Fig. S5B). We also found that the fraction of GATA6Hi embryos
more than doubled, from 15% to ∼40% (Fig. 4A,B; Fig. S5C-E).
Similar observations were made when scoring based on GATA4
staining (Fig. S5F,G). Additionally, at higher doses of LIF, we
observed a fraction of embryos that had only GATA6+ cells in the
ICM (‘GATA6 only’, Fig. 4B; Fig. S5E). Treatment with LIF had no
effect on the absolute number of trophoblast cells (Fig. S5H). We
observed a similar increase in the proportion of GATA6+ cells when
embryos were cultured from E1.5 or E3.5 until E4.5 (data not
shown). In addition, we analysed LIF-treated embryos at earlier
stages to determine how this phenotype developed over time.
Following 1 day of culture in LIF, when embryos had reached the
late morula stage, we observed no difference in the total number of
cells in embryos (Fig. S5I). However, after 2 days of culture in LIF,
at the early blastocyst stage, we observed a significant increase in
both the total number of cells in the embryo (Fig. S5J) and the
absolute number of GATA6+ PrE cells per embryo, but not in the
number of NANOG+ Epi cells (Fig. S5K). Thus, the increase in cell
number was a result of an increase in the number of GATA6+ PrE
cells in response to LIF, and this was also represented by an increase
in the proportion of GATA6Hi embryos (Fig. 4C). Treatment with
LIF also appeared to reduce the number of cells that had yet to
commit to either lineage, as the population of cells co-expressing
GATA6 and NANOG at these stages is reduced (Fig. 4C).
As we did not observe a decrease in the number of NANOG+
ICM cells (Fig. S5C), it seemed unlikely that LIF was directly acting
on cell fate to switch ICM cells from Epi to PrE. Additionally, we
had previously observed in ESCs (Morgani et al., 2013) that LIF
supported expansion of the PrE-primed population by a selective
increase in proliferation. We therefore tested whether LIF was
regulating the balance of cell types in the embryo by altering
proliferation or apoptosis in either of these lineages. Embryos were
cultured from E2.5 to E4.5 in the presence or absence of LIF and
were immunostained for NANOG, GATA6 and CDX2, as well as
for a marker of dividing cells, phospho-Ser10 HISTONE H3
(pHH3). In the presence of LIF, a slight but significant increase in
proliferation was observed in GATA6Hi embryos (Fig. 4D;
P=0.0492). To assess the level of apoptosis, we immunostained
E4.5 embryos for the three lineage markers as well as for
CLEAVED CASPASE-3 (CC3). In control, KSOM-only
conditions, we observed a significant increase in the number of
apoptotic cells in GATA6Hi embryos (P=0.0081), which was
decreased upon the addition of LIF (Fig. 4E,F). As the nuclear
Fig. 1. LIF and IL-6 promote the expansion of an extraembryonic-primed
ESC population through the JAK/STAT pathway. (A) Flow cytometry
histogram of HV ESCs cultured in 2i, 2i/LIF or 2i with increasing doses of IL-6.
(B) qRT-PCR time course of ESCs cultured in 2i for three passages before
adding LIF for up to two passages. Data are shown relative to the geometric
mean of the housekeeping genes Tbp and Pgk1. Values represent the
mean±s.d. of three biological replicates of independent ESC lines. Red dashed
lines indicate genes that are early responders to LIF (1-8 h), whereas blue
dashed lines indicate later responders (8 h or later). (C) Mean HV
fluorescence, detected by flow cytometry, after HV ESCs were cultured for
3 days in 2i/LIF in the presence of small molecule inhibitors of the PI3 K (LY)
and JAK/STAT (JAKi) pathways. Dashed line indicates the basal level of HV
fluorescence in 2i cultures. (D,E) Histogram showing flow cytometry analysis of
HV ESCs antibody stained for the LIFR. Only cells expressing the marker of
undifferentiated ESCs, SSEA-1, were analysed for the expression of the LIFR.
Either the total population was analysed (D) or the top (HV+) and bottom (HV−)
10% of HV-expressing cells were selected and analysed (E) for the expression
of LIFR. The top and bottom 10% of HV expression was also selected in
unstained and isotype control samples (see Fig. S1C) as well as in Venus
fluorescence in the E14 cell line without the HV reporter, where any difference
in signal would correspond to autofluorescence. (F) Confocal optical sections
of HV ESCs, cultured in serum/LIF, immunostained for NANOG, HV and KLF4.
White arrows indicate cells expressing low levels of NANOG but high levels of
KLF4. Yellow arrows indicate cells expressing high levels of KLF4 and HV but
low levels of NANOG. Blue arrows indicate cells that express high levels of both
NANOG and KLF4. (G) Confocal optical sections of E14 ESCs, cultured in
serum/LIF, immunostained for NANOG, pSTAT3 and KLF4. White arrows
indicate cells expressing low levels of NANOG but high levels of pSTAT3.
Yellow arrows indicate cells expressing high levels of NANOG but low levels of
pSTAT3. Blue arrows indicate cells that express high levels of NANOG and
pSTAT3.
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membrane is generally broken down in CC3+ cells, transcription
factor expression is lost and it was not possible to assign lineages to
apoptotic cells. However, when scored on physical location, we
observed a clear and significant decrease in apoptotic cells or debris
positioned adjacent to or inside the cavity (potentially originating
from PrE cells) which is also reflected in the relative increase in the
proportion of apoptotic cells in the inside of the ICM (Fig. 4F-H;
P<0.0001). There was no significant affect on proliferation or
apoptosis in NANOGHi embryos in the presence of LIF (Fig. 4D,E).
Blocking the JAK/STAT pathway leads to ICM defects,
including increased apoptosis in the PrE
As we had observed that the ability of LIF to promote a PrE-like
population in ESC cultures was mediated by JAK/STAT signalling
Fig. 2. pSTAT3 is associated with
extraembryonic lineages in the pre-
implantation embryo.
(A) Immunostaining of embryos at different
stages of pre-implantation development.
Images from blastocyst-stage embryos
represent confocal optical sections
through the ICM, whereas images of
earlier stages are extended focus,
showing the entire embryo.
(B) Quantification of co-localisation of
NANOG, GATA6 and pSTAT3 during pre-
implantation development. CellProfiler
was used to quantify immunostaining in
individual cells. Cell nuclei were
identified by manual selection and the
mean pixel intensity was measured in
arbitrary units of intensity (a.u.). Each point
represents the intensity of the noted
markers within a single nucleus. Linear
regression line is shown in red. P-values
indicate correlation.
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Fig. 3. KLF4 is expressed in both the Epi and PrE. (A) Immunostaining of embryos at different stages of pre-implantation development. Images from
blastocyst-stage embryos represent confocal optical sections through the ICM, whereas images of earlier stages are extended focus showing the entire embryo.
(B) Quantification of co-localisation of NANOG, GATA6 and KLF4 during pre-implantation development. CellProfiler was used to quantify immunostaining in
individual cells. Cell nuclei were identified by manual selection and the mean pixel intensity was measured in arbitrary units of intensity (a.u.). Each point
represents the intensity of the noted markers within a single nucleus. Linear regression line is shown in red. P-values indicate correlation.
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Fig. 4. See next page for legend.
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(Fig. 1C), we used a pharmacological inhibitor of JAK activity
(JAKi) to assess the consequences of blocking this pathway for
lineage segregation in the ICM. It was recently shown that culturing
pre-implantation embryos in JAKi caused a generic defect in ICM
maintenance (Do et al., 2013), and we aimed to understand how this
defect relates to PrE expansion. We therefore cultured embryos from
E2.5 to E4.5 in control conditions (KSOM) or in KSOMwith JAKi.
We titrated the inhibitor in ESCs and observed that, at doses
previously reported (5 μM) (Do et al., 2013), we observed
widespread cell death after 2 days (Fig. S6A,B). However, we
found that doses as low as 500 nM JAKi were sufficient to suppress
STAT3 phosphorylation. In order to minimise toxicity to embryos,
we cultured embryos at 500 nM and 100 nM. At 500 nM JAKi, we
observed no pSTAT3 in embryos and a reduction in KLF4
expression (Fig. S6C,D). At doses of 100 and 500 nM JAKi, we
observed a decrease in the number of NANOG+ cells and a slight
decrease in the number of GATA6+ ICM cells (Fig. 5A). However,
we observed obvious phenotypes in ∼50% of embryos, including
embryos cavitated without an ICM, embryos with a cavity where the
Epi should be located but still maintaining a GATA6+ PrE, and
embryos that had ICM cells that expressed neither NANOG,
GATA6 nor CDX2 (Fig. 5B,C; Fig. S6E,F). Although these cells no
longer expressed NANOG, they maintained expression of OCT4
(Fig. S6G), suggesting that they represent differentiated Epi. In
addition, we saw an increase in the proportion of embryos that had
only GATA6 or only NANOG within the ICM (Fig. 5B; Fig. S6F).
However, in embryos where there were only NANOG+ ICM cells,
the number of ICM cells was also significantly decreased, indicating
Epi defects (Fig. S6F). Little effect was observed on the number of
trophoblast cells (Fig. S6H) and, although there was a slight
decrease in total cell number in embryos without an ICM or with
cavities, this was not significant (Fig. S6I). To assess the point when
these phenotypes first become apparent, we examined embryos that
had been cultured in JAKi for one or two days. We observed no
change in the total numbers of cells at the late morula or early
blastocyst stages (Fig. S6J,K), but observed an equal increase in the
number of GATA6Hi and NANOGHi embryos in the early blastocyst
(Fig. S6L). As with the LIF-treated embryos, JAKi appeared to
accelerate the resolution of Epi and PrE lineages, reducing the
number of GATA6- and NANOG-co-expressing cells at this earlier
stage.
Apoptosis in GATA6Hi embryos was still detected and slightly
increased as a result of JAK inhibition (Fig. 5D,E). Additionally, we
observed a significant increase in the fraction of apoptotic cells
adjacent to or inside the cavity (presumably originated from PrE
cells) (Fig. 5F; P<0.05).
DISCUSSION
In this paper, we have shown that STAT3 phosphorylation, while
initially throughout the pre-implantation embryo, becomes
localized to the PrE in the late blastocyst. This suggests a role of
JAK/STAT in PrE specification that is consistent with our
observations that LIF supports extraembryonic gene expression in
ESCs. As the induction of extraembryonic gene expression in vitro
was a delayed response, it suggests that JAK/STAT acts to support a
PrE population rather than directly regulating PrE gene expression.
Thus, we observed that the activation of STAT3 could enhance the
percentage of ESCs that experienced PrE priming and increase the
proportion of PrE cells at blastocyst stages of development.
In addition to its action on PrE priming, we observed that LIF
caused the rapid downregulation of mesoderm and ectoderm
markers prior to the upregulation of PrE markers, consistent with
the fact that the mesodermmarker Lhx1 and numerousWnt pathway
components are direct targets of STAT3 (Kidder et al., 2008). This is
in keeping with previous observations that ESCs can differentiate to
PrE and form basement membrane in the presence of LIF, but that
ectoderm differentiation is blocked (Murray and Edgar, 2001). It has
been previously suggested that MEK and GSK3 inhibitors in 2i/LIF
lead to a downregulation of mesoderm and ectoderm markers, but
not of PrE markers, compared with standard serum culture
conditions (Marks et al., 2012). However, our findings suggest
that this effect is not mediated by 2i alone but also by LIF. If LIF is
able to suppress ectoderm and mesoderm differentiation, this might
explain the ability of its primary target KLF4 to drive Epi stem cells
back to a naïve mESC cell state (Guo et al., 2009). Thus, cells
induced by JAKi in vivo that express neither GATA6 nor NANOG,
but continue to express OCT4, might represent cells that have
differentiated to later Epi derivatives. Taken together, our findings
suggest that LIF acts in pre-implantation development to block Epi
differentiation and support a PrE progenitor population.
We had previously shown that LIF enhances the number of
actively proliferating PrE cells in vitro (Morgani et al., 2013), and
have shown here that it does this through the JAK/STAT pathway.
In vivo LIF had a modest effect on proliferation, which might
translate into a more robust PrE phenotype over time. However, our
exploration of the role of LIF in vivo also suggests that it acts to
suppress apoptosis in a class of embryos with an elevated proportion
of GATA6 cells. Similarly, LIF has been shown to suppress context-
dependent apoptosis in ESCs. ESCs have the capacity to eliminate
cells based on genotype as they embark on differentiation, a process
Fig. 4. Embryos cultured with LIF show an increased proportion of PrE
cells. Embryos were flushed from oviducts at E2.5 and cultured for 3 days in
KSOMwith increasing doses of LIF, 1000 U (1×), 2000 U (2×) and 5000 U (5×).
(A) Confocal optical sections through the ICM of late blastocysts
immunostained for the three lineage markers NANOG (Epi), GATA6 (PrE) and
CDX2 (trophoblast). An extended-focus image also shows the whole embryo.
(B,C) Graphs showing categorisation of immunostained embryos. Embryos
were cultured in KSOM or KSOM+LIF for 3 days (B) or 2 days (C). The ICM of
embryos was analysed based on the proportion of GATA6+ andNANOG+ cells.
Normal embryos are those with the same proportions of PrE and Epi cells as
the proportions found in the controls (KSOM-cultured) embryos ± one s.d.
GATA6Hi or NANOGHi categories correspond to embryos that fell outside of the
average control proportions±s.d. due to having more GATA6+ or NANOG+
cells. For embryos after 2 days of culture, cells that co-expressed NANOG and
GATA6 were quantified in the samemanner. The number of embryos analysed
is shown below each bar. The dashed black line indicates the proportion of
GATA6Hi embryos in control conditions. The grey dotted line indicates the
average number of embryos with high levels of GATA6 (GATA6Hi, combined
with GATA6 alone) embryos across all LIF treatments. ****P<0.0001, two-
tailed chi-square test. (D) The average number of PHOSPHO-HISTONE H3
(Ser10)+ cells (dividing cells) within E4.5 blastocysts. Error bars represent
average±s.e.m. *P=0.0492, Student’s unpaired t-test. (E) The average number
of CLEAVED CASPASE-3 (CC3)+ cells (apoptotic cells) within E4.5
blastocysts after culture from E2.5±LIF. Error bars represent average±s.e.m.
**P=0.0081, Student’s unpaired t-test. (F) Confocal image projections of whole
embryos immunostained for NANOG, GATA6 and CC3. (G) Confocal optical
sections of embryos immunostained for NANOG, GATA6, CDX2 and CC3,
demonstrating scoring categories for location of apoptotic cells, either outer
trophoblast cells, inner ICM or in the cavity either adjacent to the ICM or in the
inner cavity. (H) The physical distribution of apoptotic cells within E4.5
blastocysts after culture from E2.5±LIF, including a schematic diagram
demonstrating the scoring criteria. ‘Inner’ cells are those observed
within the inside of the ICM, ‘outer’ cells are those within the trophoblast
and ‘cavity’ cells are those that were observed within the ICM adjacent to the
cavity or within the cavity itself. ****P<0.0001, two-tailed chi-square test. As
there was little difference from 1× to 5× LIF treatment, data were combined for
panels D-G.
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mediated by competitive apoptosis that is suppressed via LIF
(Sancho et al., 2013). In ESCs, the exit from self-renewal into
differentiation triggers cell competition and associated apoptosis
(de Beco et al., 2012; Levayer and Moreno, 2013; Wagstaff et al.,
2013). Hence, selective apoptosis is perhaps triggered as a result of
PrE differentiation, and this is suppressed by limiting concentrations
of LIF.
The trophoblast expresses Lif during embryonic development,
and Lifr and Gp130 are expressed within the ICM cells (Nichols
et al., 1996). Recent single-cell microarray data also show that Lifr is
expressed at higher levels within PrE cells than in Epi cells at E3.5
and E4.5 (Ohnishi et al., 2014), consistent with our data in HV ES
cells. Moreover, these data reveal that Il-6 is expressed in the Epi,
although data on Lif expression are not clear (Ohnishi et al., 2014).
In addition, it has been shown that LIF receptors are enriched within
extraembryonic endoderm (XEN) stem cell cultures (Artus et al.,
2012). This suggests that the number of LIF/IL-6 producing cells,
outside of the PrE, calibrate the size of the PrE. When there is
insufficient PrE, excess LIF prevents apoptosis and stimulates
proliferation. However, if the PrE expands beyond a certain point,
Fig. 5. Embryos cultured with JAK inhibitor show varying phenotypes. Embryos were flushed from oviducts at E2.5 and cultured for 3 days in KSOM with
100 nM and 500 nM JAKi. (A) The average number of NANOG+ and GATA6+ cells within the ICM of E4.5 blastocysts. Points represent individual embryos.
Error bars represent average±s.e.m. (B) Categorisation of immunostained embryos. The ICM of embryos was analysed based on the proportion of GATA6+ and
NANOG+ cells. Normal embryos are thosewith the same proportions of PrE and Epi cells as the proportions found in the controls (KSOM-cultured) embryos ± one
s.d. GATA6Hi or NANOGHi categories correspond to embryos that fell outside of the average control proportions±s.d. due to having more GATA6+ or NANOG+
cells. ‘? cells’ refers to embryos in which cells were present within the ICM that expressed neither NANOG, GATA6 nor CDX2. The number below each bar
indicates the number of embryos analysed. (C) Confocal optical sections through the ICM of late blastocysts immunostained for the three lineage markers
NANOG (Epi), GATA6 (PrE) and CDX2 (trophoblast). An extended-focus image also shows thewhole embryo. (D) The average number of CLEAVEDCASPASE-
3 (CC3)+ cells (apoptotic cells) within E4.5 blastocysts after culture from E2.5±LIF. Error bars represent average±s.e.m. *P<0.05, **P<0.01; Student’s unpaired
t-test. (E) Confocal-image projections of whole embryos immunostained for NANOG, GATA6 and CC3. (F) The physical distribution of apoptotic cells within
E4.5 blastocysts after culture from E2.5±500 nM JAKi. ‘Inner’ cells are those observed within the inside of the ICM, ‘outer’ cells were those within the trophoblast
and ‘cavity’ cells are those that were observed within the ICM adjacent to the cavity or within the cavity itself. *P<0.05, two-tailed chi-square test.
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such that the available amount of LIF is insufficient to support the
size of the PrE, apoptosis ensues and the embryo recalibrates.
We also observed a requirement for JAK/STAT signalling in ICM
formation. Similar observations have been made by Solter et al. (Do
et al., 2013). Although we observed an effect of LIF on Epi
differentiation in ESCs, we detected little change in pluripotent gene
expression (Morgani et al., 2013). How, then, does JAK/STAT
signalling support self-renewal of the ICM and ESCs? One of the
principal GO terms to come out of our previous analysis of LIF
stimulation (Morgani et al., 2013) was ‘ECM components
commonly produced by the PrE’. Perhaps one mechanism by
which LIF supports the expansion of the ICM is through the
production of basement membrane required for its survival. It has
been shown in ESCs that basement membrane is important to
maintain ESCs in an undifferentiated state (Przybyla and Voldman,
2012). Additionally, the only way in which individual Epi cells
can be shown to generate ESC lines in the presence of a
pharmacological block to PrE specification (inhibition of MEK) is
by the provision of specific ECM components (Boroviak et al.,
2014). We also rarely observed embryos (3/98) in which the number
of NANOG+ cells exceeded the number of GATA6+ cells,
suggesting that a critical mass of PrE is required to support Epi
expansion. Thus, LIF could have two roles in supporting Epi
expansion, a block to later differentiation as well as a paracrine
support network that depends on the PrE.
As we found that LIF blocks later Epi differentiation, it is
not surprising that the correlation between pSTAT3 and NANOG
is lost at the late blastocyst stage, prior to Epi maturation. In vivo,
JAK/STAT signalling might only be necessary to block Epi
differentiation for a limited time window when the PrE is actively
being specified in response to the production of FGF4 by NANOG+
Epi cells (Messerschmidt and Kemler, 2010; Frankenberg et al.,
2011). This differs from the activity of LIF in ESCs in vitro, in
which we observed pSTAT3 in both NANOG+ Epi and HV+ PrE-
primed ESCs. However, ESCs exist in a state of perpetual expansion
in which these early developmental differentiation decisions are
blocked. As a result, the requirement for pSTAT3 in both
populations is prolonged indefinitely.
Taken together, our observations suggest that development of the
three primary lineages is intricately and dynamically linked. The
level of LIF secreted by the trophoblast and Epi (Nichols et al.,
1996; Ohnishi et al., 2014) might specify the number of PrE cells
within the ICM. High levels of PrE:Epi leads to apoptosis in the PrE,
whereas too little PrE would lead to a failure in Epi expansion as
a result of reduced basement membrane. We observed that
accelerating PrE expansion through the manipulation of JAK/
STAT signalling results in a loss of NANOG+GATA6+ cells in the
ICM of early blastocysts. This suggests that these sorts of paracrine
loops might have a selective role in the specification of both
lineages from the point that differentiation begins in the first few
cells. The combination of these two mechanisms would therefore be
a means by which the embryo measures the relative levels of PrE
and Epi, and ensures that both lineages are present and correctly
specified throughout early embryonic expansion.
MATERIALS AND METHODS
ESC culture and flow cytometry
E14 and HV ESCs (129/Ola background) were used in this study. ESCs
were maintained in serum/LIF or 2i medium (Morgani et al., 2013). Stat3−/−
ESCs (a kind gift from J. Nichols, Wellcome Trust-Medical Research
Council Stem Cell Institute, University of Cambridge) were maintained in 2i
or 2iLIF. ESCs were also cultured in the presence of the small molecule
inhibitors JAKi (5 µM, Calbiochem), LY294002 (5 µM, Promega) and
PD0325901 (1 µM, Sigma).
Cells were collected by trypsinisation and stained against a marker of
undifferentiated ESCs, either Pecam-1 (BD Biosciences, APC-conjugated,
551262; 1:400) or SSEA-1 (DSHB, mc480; 1:1000), and DAPI (Molecular
Probes, D1306, 100 ng/ml), to exclude dead cells (Canham et al., 2010;
Morgani et al., 2013). The anti-LIFR antibody (R&D, MAB5990) was used
at 2.5 μg/106 cells, and ESCs were stained for 30 min at room temperature
before being washed and resuspended in FACs buffer with DAPI as
described for other antibodies. Flow cytometry analysis was carried out
using a BD LSR Fortessa. Data analysis was carried out using FlowJo
software (Tree Star) by gating on forward and side scatter to identify a cell
population and eliminate debris, then gating DAPI−, viable cells before
assessing the level of Venus or APC.
ESC immunostaining
ESCs were cultured in 6-well plates on 25-mm glass coverslips coated with
gelatin or in μ-slides (Ibidi). ESC immunostaining was carried out as
previously described (Canham et al., 2010). For pStat3 staining, ESCs were
permeabilised in methanol at −20°C for 5 min. The following antibodies
were used (all at 1:200): anti-Nanog (eBioscience, 14-5761), anti-GFP
Alexa 488-conjugated (Molecular Probes, A21311), anti-Klf4 (R&D,
AF3158) and anti-pStat3 XP (Cell Signaling, 9145). Coverslips were
mounted onto glass slides using Vectashield mounting medium (Vector
Labs) and imaged by confocal microscopy using a Leica TCS SP8.
Mouse maintenance, embryo collection and culture
Both wild-type inbred C57/BL6 and outbred CD1 mouse strains were used
for these experiments. Animal work was carried in accordance with
European legislation and was authorized by and carried out under Project
License 2012-15-2934-00743 issued by the Danish Regulatory Authority.
Micewere maintained in a 12-h light/dark cycle in the designated facilities at
the University of Copenhagen, Denmark. Natural matings were set up in the
evening. Mice were checked for copulation plugs the following morning.
Embryos were flushed in PB1 medium from oviducts between E1.5 and
E2.5, and from the uterus at later stages. If culturing was needed, embryos
were cultured in KSOM medium (Millipore), to which different
concentrations of LIF or JAKi inhibitor (Calbiochem) were added. The
majority of embryos were flushed at E2.5. These embryos were then
cultured for 3 days to reach the equivalent of an E4.5 in vivo embryo. The
resulting embryos were labelled as E4.5. Embryos were cultured in distinct
microdrops for each condition, overlaid with embryo culture mineral oil
(Sigma). Embryos were culture at 37°C, 5% CO2 and 90% relative
humidity.
Embryo immunostaining and imaging
Immunostaining of embryos was carried out as previously described
(Nichols et al., 2009). When using antibodies against phospho-proteins,
embryos were permeabilised in methanol at−20°C for 5 min. The following
primary antibodies were used: anti-Nanog (eBioscience; 1:200), anti-Cdx2
(Biogenex, MU392A-UC; 1:200), anti-Gata6 XP (Cell Signaling, 5851;
1:200), anti-Gata6 (R&D, AF1700; 1:100), anti-pStat3 XP (Cell Signaling;
1:200), anti-Klf4 (R&D; 1:200), anti-phospho-Histone H3 (Ser10) (Abcam,
ab14955; 1:200), anti-Cleaved Caspase-3 (Cell Signaling, 9664; 1:200) and
anti-Gata4 (Santa Cruz, sc1237; 1:100). Embryos were imaged in an
Attofluor chamber (Invitrogen) on a 25-mm coverslip using 20×
magnification on a Leica TCS SP8 confocal microscope.
Quantification of embryo immunostaining
Confocal immunostaining of embryos was quantified using open access
software, CellProfiler (developed at MIT and the Broad Institute, USA,
www.cellprofiler.org). Individual cells stained by DAPI were identified
using a manual selection tool. To determine pSTAT3 and KLF4 levels after
treatments in PrE and Epi, GATA6 and NANOG staining, respectively, were
used to identify nuclei. Entire E1.5 and E2.5 embryos were quantified,
whereas two distinct confocal z-planes were quantified per blastocyst
stage embryo. The mean pixel intensity (measured in arbitrary units) was
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measured in each selected nucleus for all fluorescence channels, allowing a
measure of co-localisation of different markers. Results were plotted as
scatter plots in GraphPad Prism software, and correlation statistics and linear
regression analysis were carried out to generate a line of best fit. Both
C57BL/6 and CD1 embryos were utilised for quantification. As there was no
obvious difference in the results between these strains, data were combined.
Interestingly, we observed that NANOG expression turns on in only a subset
of C57BL/6 blastomeres at the 8-cell stage, whereas NANOG is present in
all blastomeres of CD1 mice at the 8-cell stage.
Embryo categorisation
The number of GATA6+ and NANOG+ ICM cells was counted in each
embryo. Control (KSOM-cultured) and LIF-treated (KSOM+LIF-cultured)
embryos were categorised as: 1, normal; 2, GATA6Hi; 3, GATA6 alone; 4,
NANOGHi; 5, NANOG alone. Embryos were categorised as ‘normal’ if
the ratio of GATA6+:NANOG+ cells was within the average of control
embryos ± one s.d. Embryos were scored as GATA6Hi if the proportion of
GATA6+ ICM cells was above this range, and as NANOGHi if the
proportion of NANOG+ ICM cells was above this range. Embryos were
scored as GATA6 or NANOG alone if the ICM consisted only of GATA6+
or NANOG+ cells. JAKi-treated embryos also exhibited distinct
phenotypes, and were hence additionally categorised as 6. No ICM, 7;
cavity (if there is an empty space where the Epi should be, still surrounded
by PrE cells), 8. A question mark denotes cells if there are unidentified cells
within the ICM expressing neither GATA6, NANOG nor CDX2. Both
C57BL/6 and CD1 embryos were utilised for quantification. As there was no
obvious difference in the results between these strains, data were combined.
Statistical analysis
Statistical analysis was performed using the QuickCalc GraphPad website
(http://www.graphpad.com/quickcalcs/index.cfm). For non-parametric data,
two-tailed chi-square tests were performed. For parametric data, unpaired
Student’s t-tests were used to determine significance. A P-value (P) is
shown wherever the difference between compared groups was significant.
As no apparent difference was observed, in some experiments with different
LIF and JAKi concentrations, data were pooled for statistical analysis.
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and Rodrıǵuez, T. A. (2013). Competitive interactions eliminate unfit embryonic
stem cells at the onset of differentiation. Dev. Cell 26, 19-30.
Singh, A. M., Hamazaki, T., Hankowski, K. E. and Terada, N. (2007). A
heterogeneous expression pattern for Nanog in embryonic stem cells. Stem Cells
25, 2534-2542.
Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G., Moreau, J., Stahl, M.
and Rogers, D. (1988). Inhibition of pluripotential embryonic stem cell
differentiation by purified polypeptides. Nature 336, 688-690.
Stewart, C. L., Kaspar, P., Brunet, L. J., Bhatt, H., Gadi, I., Köntgen, F. and
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